Correlation between microalbuminuria and glycosylated haemoglobin and cardiovascular disease in diabetic patients: a case-control study

Jayaprakash Subramani, Prabhusamy .


Background: Microalbuminuria is an independent risk factor for cardiovascular mortality in both diabetic and non-diabetic individuals. Our aim was to assess the incidence of elevated glycosylated haemoglobin and cardiovascular disease in relation to microalbuminuria in diabetic patients.

Methods: Diabetic patients with or without microalbuminuria were assigned into two groups. Each group consisted of 100 patients. Patients with co-morbid conditions which contribute to microalbuminuria were excluded from this study. Data on clinical features, fasting and postprandial blood glucose, HbA1C (glycosylated haemoglobin) level, urine microalbumin levels, renal parameters, cardiovascular events, diabetic retinopathy changes were collected for both groups and compared.

Results: Majority of patients were in 5th and 6th decade with male to female ratio of 2.5:1 in microalbuminuria group and 1:1.1 in non-microalbuminuria group. Mean duration of diabetes was 4.3 yrs in patients with microalbuminuria; and 3.5 yrs in patients without microalbuminuria. Incidence of elevated glycosylated haemoglobin (HbA1c ≥ 6.5%) in microalbuminuria group was 69%; in patients without microalbuminuria was 43%. Incidence of coronary artery disease (CAD) was 32% in microalbuminuria group; 16% in patients without microalbuminuria. These differences were statistically significant. Diabetic retinopathy was observed in 23% of patients in microalbuminuria group; 19% in patients without microalbuminuria.

Conclusions: Microalbuminuria in diabetic patients was significantly associated with poor glycaemic control. It was strongly associated with longer duration of diabetes. Incidence of cardiovascular events was higher in patients with microalbuminuria compared to patients without microalbuminuria.


Microalbuminuria, Glycosylated haemoglobin, Cardiovascular disease

Full Text:



Danaei G. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2•7 million participants. The Lancet. 2000;378,9785:31-40.

Diabetes country profile data by World health organisation (WHO). 2016. Available at

Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin and mean glucose levels over time. Diabetologia. 2007;50:2239-44.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.

Jarret RJ, Viberti GC, Argyropoulos A. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabetic Med. 1984;1:17-9.

Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Eng J Med. 1984;310:356-60.

Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;7:996-1003.

Stehouwer CDA, Nauta JJ, Zeldenrust GC. Urinary albumin excretion cardiovascular disease and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319-23.

Gall MA, Rossing P, Skott P. Prevalence of micro and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991;34:655-61.

Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic ratinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care. 1996;19:1243-8.

Lee KU, Park JY, Kim SW. Prevalence and associated features of albuminuria in Koreans with NIDDM. Diabetes Care. 1995;18:793-5.

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-59.

Garg JP, Bakris GL, Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease, Vascular Medicine. 2002;7:35-43.

Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996;5:219-23.

Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T. Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care. 1992;15:1181-91.

Varghese A, Deepa R, Rema M, Mohan V. Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India, Postgrad Med J. 2001;77:399-402.

Gupta DK, Verma LK, Khosla PK. The prevalence of microalbuminuria in diabetes: a study from north India. Diabetes Res Clin Pract. 1991;12:125-8.

Klein R, Klein BEK, Moss SE. Prevalence of microalbuminuria in older-onset-diabetes. Diabetes Care. 1993;16:1325-9.

Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes: a 1-year follow-up study of 503 patients. Diabet Med. 1987;5:126-34.

Hillege HL, Fidler V, Diercks GF. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777-82.

Namperumalsamy P, Kim R, Vignesh TP, Nithya N, Royes J. Prevalence and risk factors for diabetic retinopathy: a population-based assessment from Theni District, south India. Br J Ophthalmol. 2009;93:429-34.